0 CHECKOUT

Fatigue - Pipeline Review, H1 2015

  • ID: 3099677
  • January 2015
  • 33 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biovista Inc.
  • Merz Pharmaceuticals GmbH
  • PharmaLundensis AB
  • MORE

Fatigue - Pipeline Review, H1 2015

Summary

This, ‘Fatigue - Pipeline Review, H1 2015’, provides an overview of the Fatigue’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biovista Inc.
  • Merz Pharmaceuticals GmbH
  • PharmaLundensis AB
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Fatigue Overview
Therapeutics Development
Pipeline Products for Fatigue - Overview
Pipeline Products for Fatigue - Comparative Analysis
Fatigue - Therapeutics under Development by Companies
Fatigue - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fatigue - Products under Development by Companies
Fatigue - Companies Involved in Therapeutics Development
Biovista Inc.
Dimerix Bioscience Pty Ltd
Hemispherx Biopharma, Inc.
Merz Pharmaceuticals GmbH
MultiCell Technologies, Inc.
PharmaLundensis AB
Teva Pharmaceutical Industries Limited
Fatigue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fatigue - Dormant Projects
Fatigue - Product Development Milestones
Featured News & Press Releases
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fatigue, H1 2015
Number of Products under Development for Fatigue - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Fatigue - Pipeline by Biovista Inc., H1 2015
Fatigue - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015
Fatigue - Pipeline by Hemispherx Biopharma, Inc., H1 2015
Fatigue - Pipeline by Merz Pharmaceuticals GmbH, H1 2015
Fatigue - Pipeline by MultiCell Technologies, Inc., H1 2015
Fatigue - Pipeline by PharmaLundensis AB, H1 2015
Fatigue - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Fatigue - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Fatigue, H1 2015
Number of Products under Development for Fatigue - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Biovista Inc.
Dimerix Bioscience Pty Ltd
Hemispherx Biopharma, Inc.
Merz Pharmaceuticals GmbH
MultiCell Technologies, Inc.
PharmaLundensis AB
Teva Pharmaceutical Industries Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.